FDA approves new uses for Natera's MRD test

By LabPulse.com staff writers

March 24, 2021 -- The U.S. Food and Drug Administration (FDA) has granted two breakthrough device designations covering new intended uses for Natera's Signatera molecular residual disease (MRD) test.

The new designations will support the development of Signatera through phase III clinical trials as a companion diagnostic to different solid tumor indications and cancer therapies.

Signatera is a custom-built circulating tumor DNA (ctDNA) test that is available for clinical and research use. The test is used for treatment monitoring and MRD assessment in patients previously diagnosed with cancer.

Copyright © 2021 LabPulse.com

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?